Pathology of Urothelial Cancers
Dr. Donna E. Hansel, MD, PhD discusses molecular pathology in clinical practice and urothelial cancer treatment.
Read MoreSelect Page
Posted by Donna E. Hansel, MD, PhD | Dec 2022
Dr. Donna E. Hansel, MD, PhD discusses molecular pathology in clinical practice and urothelial cancer treatment.
Read MorePosted by Kidney Cancer Journal | Dec 2022
Immune Checkpoint Inhibitors in the Pre-operative Setting and Impact on the Primary Renal Tumor...
Read MorePosted by Gregory F. Murphy, MD | Dec 2022
Congressman Gregory F. Murphy, MD, a practicing urologist and the Representative from North Carolina’s 3rd District, speaks with E. David Crawford, MD, Editor-in-Chief of Grand Rounds in Urology, about the dual impact of increasing inflation and decreasing medicare conversion rates on physician reimbursement. Dr. Murphy refers to the upcoming 4.42% decrease in medicare conversion factors and how it will have an outsized impact on physicians in private practice, especially as inflation has topped 8% in the past year. The two also discuss how certain technologies, such as robotic surgery and disposable cytoscopes, increase costs for physicians, and how cost efficiency should be taught starting in residency programs.
Read MorePosted by Veda N. Giri, MD | Dec 2022
In this 6-minute video, Veda N. Giri, MD, Division Chief of Clinical Cancer Genetics at Yale and Assistant Director of Clinical Cancer Genetics at Yale Cancer Center, discusses the virtual genetics board for enhancing knowledge and practice of prostate cancer genetic testing and the ENGAGEMENT study. She explains that this board aims to elucidate genetics topics from PCa germline testing to genetic counseling.
Read MorePosted by E. David Crawford, MD | Dec 2022
E. David Crawford, MD, Philip J. Koo, MD, and David M. Albala, MD, present seven abstracts highlighting PMSA PET imaging and its impact on prostate cancer management.
Read More